



(11)

**EP 2 699 590 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Bibliography INID code(s) 73**

(51) Int Cl.:  
**A61K 38/00 (2006.01)**

(86) International application number:  
**PCT/US2012/034295**

(48) Corrigendum issued on:  
**17.04.2019 Bulletin 2019/16**

(87) International publication number:  
**WO 2012/145539 (26.10.2012 Gazette 2012/43)**

(45) Date of publication and mention  
of the grant of the patent:  
**20.02.2019 Bulletin 2019/08**

(21) Application number: **12717013.2**

(22) Date of filing: **19.04.2012**

---

(54) **ENDOGLIN POLYPEPTIDES AND USES THEREOF**

ENDOGLINPOLYPEPTIDE UND IHRE VERWENDUNG

POLYPEPTIDES D'ENDOGLINE ET LEURS UTILISATIONS

---

(84) Designated Contracting States:  
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB**  
**GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO**  
**PL PT RO RS SE SI SK SM TR**

(74) Representative: **EIP**  
**EIP Europe LLP**  
**Fairfax House**  
**15 Fulwood Place**  
**London WC1V 6HU (GB)**

(30) Priority: **20.04.2011 US 201161477585 P**

(56) References cited:  
**WO-A1-2007/143023 WO-A1-2008/151078**

(43) Date of publication of application:  
**26.02.2014 Bulletin 2014/09**

(60) Divisional application:  
**19150039.6**

(73) Proprietor: **Accelaron Pharma Inc.**  
**Cambridge, MA 02139 (US)**

- **FRANCISCO J. BLANCO ET AL: "Interaction and functional interplay between endoglin and ALK-1, two components of the endothelial transforming growth factor-[beta] receptor complex", JOURNAL OF CELLULAR PHYSIOLOGY, vol. 204, no. 2, 1 August 2005 (2005-08-01), pages 574-584, XP055030607, ISSN: 0021-9541, DOI: 10.1002/jcp.20311**
- **SCHARPFENECKER MARION ET AL: "BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis", JOURNAL OF CELL SCIENCE, vol. 120, no. 6, 1 March 2007 (2007-03-01), pages 964-972, XP002490785, CAMBRIDGE UNIVERSITY PRESS, LONDON, GB ISSN: 0021-9533, DOI: 10.1242/JCS.002949**

(72) Inventors:

- **GRINBERG, Asya**  
**Lexington, MA 02421 (US)**
- **CASTONGUAY, Roselyne**  
**Malden, MA 02148 (US)**
- **WERNER, Eric**  
**Milton, MA 02186 (US)**
- **KUMAR, Ravindra**  
**Acton, MA 01720 (US)**

---

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 2 699 590 B8**

- R. CASTONGUAY ET AL: "Soluble Endoglin Specifically Binds Bone Morphogenetic Proteins 9 and 10 via Its Orphan Domain, Inhibits Blood Vessel Formation, and Suppresses Tumor Growth", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 286, no. 34, 26 August 2011 (2011-08-26), pages 30034-30046, XP055031457, ISSN: 0021-9258, DOI: 10.1074/jbc.M111.260133
- ALT AARON ET AL: "Structural and functional insights into endoglin ligand recognition and binding.", PLOS ONE, vol. 7, no. 2, E29948, 8 February 2012 (2012-02-08), pages 1-12, XP002679013, ISSN: 1932-6203